xRead - September 2022

Wise et al.

Page 389

Author Manuscript Author Manuscript Author Manuscript Author Manuscript Clinical endpoint Conclusion 2 Placebo

Nasal symptoms IPB is effective in controlling rhinorrhea.

Nasal symptoms IPB had a significant effect on rhinorrhea. No effect on other symptoms. Nasal symptoms, QOL

Nasal symptoms IPB is effective in controlling rhinorrhea. Nasal symptoms, medication use, QOL

Equally effective in controlling rhinorrhea and improving QOL. BDP more effective in controlling sneezing.

IPB was effective in controlling rhinorrhea, congestion, postnasal drip, and sneezing. Reduction in the use of medications and improvement in QOL.

Kaiser et al. 1390 1995 2b Prospective PAR, 18–75 years old (n = 219): First 6 months: 0.06% IPB TID (84 μ g); 6 months to 1 year: lowest dose IPB controlling rhinorrhea

Kim et al. 1378 2005 2b Prospective Common cold, SAR or PAR; 2–5 years old (n = 230); Allergy group: IPB 0.06%, 1 spray (42 μ g) TID for 14 days (n = 187) Milgrom et al. 1389 1999 2b RCT, blinded, no placebo 1 IPB 0.03% nasal spray (42 μ g), 2 sprays BID (n = 75); 2 BDP (n = 71)

1 IPB 1 puff 20 μ g QID; 2 Placebo

Study Year LOE Study design Study groups Schultz Larsen et al. 1387 crossover 1 IPB 80 μ g QID; 2 Placebo

PAR, 23–84 years old (n = 20):

PAR, 18–82 years old (n = 20):

PAR, non-allergic perennial rhinitis, 6–18 years old:

crossover

1983 1b RCT,

Borum et al. 1388 1979 1b RCT,

BDP = beclomethasone dipropionate; DBRCT = double-blind randomized controlled trial; IPB = ipratropium bromide; LOE = level of evidence; NAR = non-allergic rhinitis; PAR = perennial allergic rhinitis; QID = 4 times daily; QOL = quality of life; RCT = randomized controlled trial; SAR = seasonal allergic rhinitis; TID = 3 times daily; BID = 2 times daily.

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.